# Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

> **NCT06860178** · PHASE4 · RECRUITING · sponsor: **Epicentre** · enrollment: 40000 (estimated)

## Conditions studied

- Malaria Vaccine

## Interventions

- **OTHER:** Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months

## Key facts

- **NCT ID:** NCT06860178
- **Lead sponsor:** Epicentre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2026-05
- **Final completion:** 2027-12
- **Target enrollment:** 40000 (ESTIMATED)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06860178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06860178, "Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06860178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*